Archive

GLP-1 RAs – where are we now? What have we learned?

Written by Christine Clark | 17 Mar 2025

Pharmacist Deborah Evans runs a weight-management clinic at Remedi Health in Winchester. She has helped many people to lose weight and improve their health using the GLP-1 receptor… read more.

Taking semaglutide before bariatric surgery does not improve weight loss or safety

Written by Charlie King | 15 Mar 2025

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery, suggesting that a surgery first strategy… read more.

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

Written by Charlie King | 5 Mar 2025

Eli Lilly and Company announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program… read more.

SGLT-2 drug plus moderate calorie restriction achieves higher diabetes remission

Written by Charlie King | 9 Feb 2025

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher… read more.

What’s the mechanism behind behavioral side effects of popular weight loss drugs?

Written by Charlie King | 25 Jan 2025

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have… read more.

Novo Nordisk announced headline results from STEP UP, a phase IIIb trial investigating subcutaneous semaglutide 7.2 mg for obesity

Written by Charlie King | 22 Jan 2025

Novo Nordisk announced headline results from STEP UP, a phase IIIb trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous… read more.

MHLW (Japan) approves Zepbound (tirzepatide) to treat obesity – Eli Lilly KK + Mitsubishi Tanabe

Written by Charlie King | 12 Jan 2025

Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation announced that Eli Lilly Japan received manufacturing and marketing authorization in Japan from the Japanese Ministry of Health, Labour… read more.

GLP-1 RA drugs effectively treat obesity in adults without diabetes

Written by Bruce Sylvester | 7 Jan 2025

A meta- analysis of studies evaluating the efficacy and safety of various glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for treating obesity in adults without diabetes, suggests… read more.

NICE (UK) positive for Zepbound (tirzepatide) for managing overweight and obesity – Eli Lilly

Written by Charlie King | 6 Jan 2025

NICE (UK): 1.1 Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have:… read more.

Walking speed predicts metabolic health in obese individuals

Written by Gary Finnegan | 29 Dec 2024

The speed at which people walk can provide insights into health, extending beyond mere mobility, according to experts in Japan. Past studies have suggested that a slow walking… read more.

FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity – Eli Lilly

Written by Charlie King | 26 Dec 2024

Eli Lilly and Company announced the FDA approved Zepbound (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Zepbound… read more.

Ultraprocessed foods account for more than half of calories consumed at home

Written by Charlie King | 15 Dec 2024

A new analysis led by researchers at the Johns Hopkins Bloomberg School of Public Health found that more than half of calories consumed at home by adults in… read more.

« Previous 1 2 3 4 5 6 … 20 Next »

Archive

Subscribe for our mailing list

Follow Us